Key Highlights
• Shares traded at $19.92 pre-market, down 6.21% from the $21.24 prior close.
• Third-quarter Revenue of $342 million was up 22% year over year on an adjusted basis.
• DAYBUE net sales reached a record $140 million, up 39%.
• Adjusted EPS of $0.31 compared with an estimate of $0.19.
• The Phase 2 Radiant study of remlifanserin did not meet its primary endpoint, with a p-value of 0.0603.
Acadia Pharmaceuticals (NASDAQ:ACAD) shares were trading lower in pre-market activity on Friday, November 6, after the company reported third-quarter 2026 results. The San Diego-based company was founded in 1993 and is a commercial-stage biopharmaceutical company developing small molecule therapies for central nervous system and rare neurological diseases.
Its two FDA-approved products are NUPLAZID, for hallucinations and delusions associated with Parkinson's disease psychosis, and DAYBUE, which contains trofinetide, licensed from Neuren, for Rett syndrome. The company's profile lists about 800 employees.
Record DAYBUE Sales and Third-Quarter Results
Third-quarter total revenues were $342 million, up 22% year over year on an adjusted basis, against estimates of $332.6 million. DAYBUE net sales reached a record $140 million, up 39%, with almost all of the growth from volume. NUPLAZID net sales were $202 million, up 12% on an adjusted basis.
Adjusted EPS was $0.31, compared with estimates of $0.19. For 2026, the company expects R&D expenses of $325 million to $340 million and SG&A expenses of $665 million to $685 million. Cash was $976 million at quarter end.
Raised DAYBUE Outlook and Pipeline Update
Full-year 2026 total revenues are now expected to be between $1.265 billion and $1.295 billion. DAYBUE guidance was raised to $505 million to $520 million, while NUPLAZID guidance was narrowed to $760 million to $775 million. Management reiterated its ambitions of $700 million in DAYBUE sales and about $1 billion in NUPLAZID sales by the end of 2028.
The company received a USPTO notice of allowance for a weight-banded dosing Patent that would extend U.S. protection for DAYBUE to March 2041. In Alzheimer's disease psychosis, the Phase 2 Radiant study did not meet its primary endpoint, with a p-value of 0.0603. The Phase 3 trial will drop the 30 mg arm, and FDA discussions are expected in the first half of 2027.
Outlook: Phase 3 Design, FDA Discussions and Upcoming Readouts
Acadia expects the full benefit of its expanded NUPLAZID field force to appear through late 2026 and into 2027. Items to watch include FDA discussions in early 2027, Phase 2 results for Lewy body dementia psychosis in the fourth quarter of 2027, and Phase 2 data for ACP-211 in depression in the second half of 2027. The company also expects to file DAYBUE in Japan in 2027, with a targeted 2028 launch.



_11_19_2026_18_10_09_455845.jpg)

_11_19_2026_18_15_38_890267.jpg)
Please wait processing your request...